LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Kitov Pharmaceutical Holdings Ltd. (“Kitov” or the “Company”) (Nasdaq: KTOV) concerning possible violations of federal securities laws.
If you purchased or otherwise acquired Kitov shares and would like more information regarding the investigation, we encourage you to click here, or contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at email@example.com.
On February 6, 2017, the Israeli publication Calcalist published that Kitov’s Chief Executive Officer, Isaac Israel, had been detained by the Israeli Securities Authority due to allegations of publishing misleading information regarding a recent clinical trial of one of Kitov’s products.
When this information was released to the public, the value of Kitov stock fell, causing investors harm.
If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at firstname.lastname@example.org.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.